N/A N=12 Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Immediate Verbal Memory — 15.85; 17.36; 14.97; 13.28 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=83 Accommodation Disorders
Accommodative Insufficiency · Ill-sustained Accommodation
Primary: Accommodation Lag 5D — 0.9 diopters
Phase 3 N=773 Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Mean Trough Forced Expiratory Volume in 1 Second (FEV1) (NVA237 Versus Tiotropium) — 0.095; 0.102 liters
Phase 3 N=240 Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events — 6; 7; 136; 84 participants
N/A N=263 Homeopathic Cold Remedy for Children Study
Upper Respiratory Tract Infections
Primary: Change in Severity of Cold Symptoms — 3.7; 3.7; 3.9; 3.9 units on a scale — p=.86
Phase 4 N=152 Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2 — 1.490; 1.453 liters per hour
N/A N=110 Home-Based Exercise and Weight Control Program for Pain Control in Overweight Elderly With Osteoarthritis of the Knee
Chronic Diseases · Obesity · Osteoarthritis
Primary: WOMAC Function — -10.4; -4.8; -4.9; -1.6 Change in Score — p=0.0129
Phase 2 N=34 A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
Cancer · Pain
Primary: Time-weighted SPID30 — 59.9; 42.6 units on a scale — p=<0.001
Phase 2 N=16 Treatment of Liver Metastases With Electrochemotherapy
Liver Metastases
Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events
Phase 1 N=25 Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients
Ischemic Stroke
Primary: Study Related Serious Adverse Events (SR-SAE) — 0 Events
Phase 3 N=503 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: Overall Survival — 0.52; 0.57 percentage of 5 years survival rate — p=0.14
Phase 2 N=33 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Breast Cancer · Hypercalcemia of Malignancy · Colon Cancer
Primary: Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab — 63.6 percentage of participants
N/A N=157 Spinal Cord Injury Vocational Integration Program (SCI-VIP)
Spinal Cord Injuries
Primary: Competitive Employment-Total Jobs — 50; 21 Total Competitive Employments
Phase 4 N=169 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
Thrombocytopenia · Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants With Collagen Fibrosis — 0.0; 0.0; 3.4 percentage of participants
Phase 1 N=18 Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 18048; 16007; 17042 ng/mL